or
Bookmark and Share
Increasing the bioavailability of alpha-etiocholanolone
   
Document Number
US Patent 4871726
Issued Date
October 3, 1989
Link
Inventors
Map
Abstract
Methods and compositions are disclosed for inducing an incresed blood level of alpha-etiocholanolone in the body of a mammal in need of such treatments comprising administering to said mammal an amount of etiocholanedione effective to induce said increased blood level.
Tags:
Description:
Amusing 0%
Clever 0%
Complex 0%
Efficient 0%
Historic 0%
Important 0%
Innovative 0%
Interesting 0%
Practical 0%
Simple 0%
Number of Claims:
18
Comments:
no comments yet
Owner
Progenics, Inc. (New York, NY)
Published
October 3, 1989
Application Number
07/078,610
Filed
July 28, 1987
US Classification
514/177  
Int'l Classification
A61K   31/565   (20060101)  
USPTO Field of Search
514/177  
Related Patents
5527788 - Method and composition for treating obesity comprising dehydroepiandrosterone (DHEA), or a derivative thereof, and an anorectic agent - Owned by Louisiana State Univ. Medical Center Foundation (New Orleans, LA)

The invention describes a method and composition for treating obesity or related disorders in animals using an anorectic agent and dehydroepiandrosterone (DHEA). The composition effectively diminishes caloric intake, may alter metabolism, weight gain, or a combination thereof.

5795880 - Method and composition for treating obesity and related disorders in animals comprising dehydroepiandrosterone (DHEA), or a derivative thereof, and an anorectic agent - Owned by Louisiana State University Medical Center Foundation (New Orleans, LA)

The invention describes a method and composition for treating obesity or related disorders in animals using an anorectic agent and dehydroepiandrosterone (DHEA). The composition effectively diminishes caloric intake, may alter metabolism, weight gain, or a combination thereof.

5824668 - Formulation for administration of steroid compounds - Owned by Supergen, Inc. (San Ramon, CA)

Disclosed are compositions including at least one 5.beta. steroid and an amorphous cyclodextrin. Also disclosed are methods for treating a condition such as obesity, diabetes syndrome, diabetes-associated hypercorticoidism, combinations thereof, and anemic disorders by administering to a mammal in need of such treatment a composition including an obesity-, diabetes-, or anemia antagonistic amount of at least one 5.beta. steroid and an amorphous cyclodextrin. Furthermore, disclosed are methods for treating a subject for a condition that responds to treatment with DHEA by administering to the subject at least one 5.beta. steroid and DHEA in an amount that minimizes the contribution of the DHEA to the production of testosterone and estradiol while maximizing an amount of .alpha.ET and .beta.ET circulating in the subject's blood from an initial dose administered to the subject.

Claims
Description
About| FAQs| Terms & Disclaimer| Link to Us| Contact Us